Efficacy and safety of switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) in virologically suppressed women
Journal of Acquired Immune Deficiency Syndromes | May 27, 2018
Most read this week
Journal of Acquired Immune Deficiency Syndromes | May 27, 2018